TriSalus Life Sciences (TLSI) Operating Margin (2022 - 2026)

TriSalus Life Sciences has reported Operating Margin for 5 years, with the latest figure at 94.52% in Q1 2026.

• For the quarter ending Q1 2026, Operating Margin fell 1457.0% year-over-year to 94.52%; the trailing twelve-month figure through Mar 2026 stood at 62.45% (up 3656.0% YoY), and the FY2025 full-year result was 59.68%, up 6320.0% from the prior year.
• Operating Margin for Q1 2026 stood at 94.52%, down from 24.77% in the prior quarter.
• The five-year high for Operating Margin was 24.77% in Q4 2025, with the low at 364.91% in Q4 2022.
• Historically, Operating Margin has averaged 174.09% across 5 years, with a median of 118.91% in 2024.
• Annual changes were most pronounced in 2023 — Operating Margin sank 15173 bps — and 2024, when it surged 23957 bps.
• TriSalus Life Sciences' Operating Margin stood at 364.91% in 2022, then soared by 32 bps to 249.05% in 2023, then soared by 63 bps to 91.76% in 2024, then jumped by 73 bps to 24.77% in 2025, then tumbled by 282 bps to 94.52% in 2026.
• The last three Operating Margin figures came in at 94.52% (Q1 2026), 24.77% (Q4 2025), and 77.94% (Q3 2025), per Business Quant data.